
Consortium sells LAB901
Archangel Informal Investment, Alliance Trust, Scottish Enterprise, Foresight, Noble Fund Managers and the Business Growth Fund have exited their stake in LAB901.
The company, a developer and supplier of platform technology instruments that analyse DNA, RNA and protein fragments, was purchased by measurement company Agilent Technologies.
A team led by Janita Good from law firm Osborne Clarke advised the management team, while Mark Barron and colleagues from Taylor Wessing supported the acquirer.
Noble Fund Managers entered into LAB901 in August 2006, leading a £1.5m series-D funding round alongside existing investor Archangel.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater